Three-year adjusted probabilities of disease-free survival, relapse, nonrelapse mortality, overall survival, chronic GVHD, and day 100 acute grade II to IV acute GVHD
| Outcome . | Myeloablative regimen (95% CI), % . | Reduced-intensity regimen (95% CI), % . | P . |
|---|---|---|---|
| Disease-free survival | |||
| Age, 18-54 y | 47 (41-52) | 35 (29-41) | .009 |
| Age, 55-70 y | 40 (32-49) | 33 (28-38) | .15 |
| Relapse | |||
| Age, 18-54 y | 38 (32-43) | 51 (44-57) | .003 |
| Age, 55-70 y | 34 (25-43) | 46 (41-51) | .03 |
| Nonrelapse mortality | |||
| Age, 18-54 y | 18 (14-22) | 17 (12-22) | .81 |
| Age, 55-70 y | 30 (22-38) | 24 (19-30) | .26 |
| Overall survival | |||
| Age, 18-54 y | 54 (49-60) | 49 (42-55) | .19 |
| Age, 55-70 y | 42 (33-50) | 38 (33-43) | .48 |
| Acute grade II-IV GVHD | |||
| Age, 18-54 y | 24 (20-28) | 20 (15-25) | .23 |
| Age, 55-70 y | 23 (16-30) | 20 (17-24) | .52 |
| Chronic GVHD | |||
| Age, 18-54 y | 38 (29-47) | 38 (33-43) | .97 |
| Age, 55-70 y | 26 (19-34) | 28 (23-32) | .75 |
| Outcome . | Myeloablative regimen (95% CI), % . | Reduced-intensity regimen (95% CI), % . | P . |
|---|---|---|---|
| Disease-free survival | |||
| Age, 18-54 y | 47 (41-52) | 35 (29-41) | .009 |
| Age, 55-70 y | 40 (32-49) | 33 (28-38) | .15 |
| Relapse | |||
| Age, 18-54 y | 38 (32-43) | 51 (44-57) | .003 |
| Age, 55-70 y | 34 (25-43) | 46 (41-51) | .03 |
| Nonrelapse mortality | |||
| Age, 18-54 y | 18 (14-22) | 17 (12-22) | .81 |
| Age, 55-70 y | 30 (22-38) | 24 (19-30) | .26 |
| Overall survival | |||
| Age, 18-54 y | 54 (49-60) | 49 (42-55) | .19 |
| Age, 55-70 y | 42 (33-50) | 38 (33-43) | .48 |
| Acute grade II-IV GVHD | |||
| Age, 18-54 y | 24 (20-28) | 20 (15-25) | .23 |
| Age, 55-70 y | 23 (16-30) | 20 (17-24) | .52 |
| Chronic GVHD | |||
| Age, 18-54 y | 38 (29-47) | 38 (33-43) | .97 |
| Age, 55-70 y | 26 (19-34) | 28 (23-32) | .75 |